A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
Key Inclusion Criteria:
Key Exclusion Criteria:
Wuhan, 430022, China
Essen, 45136, Germany
Rambam, 3525408, Israel
Wroc?aw, 53-413, Poland
Krasnoyarsk, Krasnodarskiy Kray 660133, Russia
Moscow, Moscow Oblast 115478, Russia
Saint Petersburg, Sankt-Peterburg 197022, Russia
Kazan', Tatarstan Republic 420029, Russia
Jeollanam-do, 58128, South Korea
Kaohisung, Taiwan
Adana, 01250, Turkey (Türkiye)
Erzurum, 25240, Turkey (Türkiye)
Kharkiv, Kharkiv Governorate 61070, Ukraine